Iluria Health

Precision-monitoring platform for ADHD treatment using physiological data from commercial wearables.

Website: https://www.iluriahealth.com/

Cover Block

Public sources

Field Detail
Name Iluria Health
Tagline Precision-monitoring platform for ADHD treatment using physiological data from commercial wearables. [iluriahealth.com]
Headquarters Hod Hasharon, Israel [ContactOut]
Founded 2018 [ContactOut]
Stage Seed [Iluria LinkedIn, June 2022]
Business model B2B2C
Industry Healthtech
Technology AI / Machine Learning [iluriahealth.com]
Geography Middle East / North Africa
Growth profile Venture Scale
Founding team Hagay Levy, Birkat Klimshtein Levy [Hagay Levy / LinkedIn] [Birkat Klimshtein Levy / LinkedIn]
Funding label Seed
Total disclosed funding $850,000 [Iluria LinkedIn, June 2022]

Links

Public sources

Executive Summary

PUBLIC Iluria Health is an Israeli digital-health startup building a wearable-based precision-monitoring platform for ADHD treatment, and it merits attention because it is trying to turn a subjective medication-titration process into a continuous data layer for clinicians and families [iluriahealth.com] [ContactOut] [LinkedIn, June 2024]. Founded in 2018 in Hod Hasharon, the company appears to have been shaped in part by lived experience: co-founders Hagay Levy and Birkat Klimshtein Levy both publicly link the company’s origin to deep familiarity with ADHD, while Levy has also described a prior career in Israeli capital markets and finance-related operating roles [ContactOut] [LinkedIn Pulse, January 2023] [Xceptional Leaders podcast, August 2026].

The product case rests on software rather than hardware. Iluria says it analyzes physiological data from commercial wearables, including movement, heart rate, and heart rate variability, and uses machine learning to generate personalized, real-time feedback for treatment decisions, which is a more specific wedge than a general mental-health app if the clinical signal proves durable in practice [iluriahealth.com] [LinkedIn, June 2024]. Public evidence on validation is still early: the company says its decision-support tool has completed four clinical studies, and separate company materials refer to clinical trials with Cincinnati Children’s Hospital Medical Center and Clalit Health Services, but those claims remain largely company-sourced and do not yet establish commercial deployment [Hagay Levy / LinkedIn] [iluriahealth.com] [CB Insights].

The team profile is more commercial and operational than research-heavy in the public record. Iluria identifies Hagay Levy as CEO, Birkat Klimshtein Levy as co-founder and director, and Ran Izraeli as VP of Product and Corporate Development; the founders describe decades of managerial, project, and financial experience, while public materials are thinner on named clinical or technical leadership beyond advisory recruiting efforts seen in 2025 job posts [Hagay Levy / LinkedIn] [Birkat Klimshtein Levy / LinkedIn] [iluriahealth.com] [LinkedIn, March 2025] [LinkedIn, December 2025].

On capitalization, the clearest disclosed figure is the company’s June 2022 statement that it had secured $850,000 in cumulative dilutive investment, with investors named across sources including Health Wildcatters, LUMUS Investment Collective, Innosphere Ventures, Pareto Holdings, EIT Health, and 8200 Impact [LinkedIn, June 2022] [D Magazine, September 2020] [PitchBook]. The business model is framed as B2B2C, with public materials pointing to physicians, clinics, providers, and payers as stakeholder groups and to private mental-health clinics as an initial commercialization path, so the next 12 to 18 months should be watched for evidence of repeatable customer deployments, clearer clinical outcomes, and a financing record that reconciles conflicting third-party funding tallies [LinkedIn, March 2025] [iluriahealth.com] [CB Insights] [PitchBook].

Company-stated, unverified -- This section relies materially on company website claims, founder LinkedIn materials, and a company LinkedIn funding post, with only partial corroboration from third-party databases and interviews.

Taxonomy Snapshot

Axis Value
Stage Seed
Business Model B2B2C
Industry / Vertical Healthtech
Technology Type AI / Machine Learning
Geography Middle East / North Africa
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding Seed, total disclosed approximately $850,000 [LinkedIn, June 2022]

How the Company Got Here

PUBLIC

Iluria Health presents as an Israeli digital-health company focused on ADHD treatment monitoring through data gathered from commercial wearables [iluriahealth.com]. The public record places the company in Hod Hasharon, Israel, and indicates a 2018 founding date, which matters because it frames Iluria less as a newly formed concept and more as a team that has been working at the problem for several years [ContactOut].

The chronology that can be supported from company materials is narrow but still useful. On its website, Iluria describes a precision-monitoring platform intended to give clinicians and families continuous feedback on ADHD treatment response, and it says the company completed clinical trials with Cincinnati Children’s Hospital Medical Center and Clalit Health Services [iluriahealth.com]. In June 2022, the company stated on LinkedIn that it had secured $850,000 in cumulative dilutive investment, naming Health Wildcatters, LUMUS Investment Collective, and angel investors among the backers [LinkedIn, June 2022].

That leaves a company profile that is directionally clear even if the public evidence base remains thin. The main milestones visible in public sources are the 2018 formation, subsequent clinical-trial work described by the company, and an early seed financing disclosed in mid-2022 [ContactOut] [iluriahealth.com] [LinkedIn, June 2022].

Company-stated, unverified -- This section relies primarily on company website statements and a company LinkedIn funding post, with only partial corroboration for the founding date from ContactOut.

Product and Technology

Product and Technology

MIXED The product story is relatively clear even though the underlying evidence is still company-led. Iluria Health describes its software as a precision-monitoring platform for ADHD treatment that ingests physiological data from commercial wearables and returns continuous, objective feedback for clinicians and families [Iluria Health]. In the company’s public materials, the stated goal is to reduce the trial-and-error process around ADHD medication and treatment adjustment by measuring response outside the clinic [Iluria Health]; a June 2024 LinkedIn post describing the company’s video presentation frames the wedge in similar terms, as remote monitoring for treatment decisions rather than a new therapeutic or diagnostic device [LinkedIn, June 2024].

The company says the system collects wearable-derived signals including movement, heart rate, and heart rate variability, then applies machine learning to generate personalized, real-time output for treatment decisions [Iluria Health]. That claim establishes the product concept, but not yet its clinical performance in market settings. Public evidence does point to some validation work: Iluria says its wearable-based decision-support tool has completed four clinical studies [Hagay Levy / LinkedIn], and the company’s About page says it completed two clinical trials with Cincinnati Children’s Hospital Medical Center and Clalit Health Services [Iluria Health]. Those statements support a view that the product is being tested in clinical contexts, while leaving open key diligence questions on regulatory positioning, workflow integration, and whether clinicians receive a dashboard, report, or alerting layer as the primary interface.

The technology stack itself is only partially visible from public materials. There is clear evidence for commercial wearables as the data source and machine learning as the analysis layer [Iluria Health], but no public documentation in the supplied sources on model architecture, specific wearable partners, interoperability standards, or deployment environment. Advisory-board recruiting materials do suggest the company is already thinking about go-to-market surfaces across providers, payers, and mental-health clinics [LinkedIn, March 2025], which is consistent with a B2B2C operating model, but that is a commercial signal rather than a technical one.

Company-stated, unverified -- Material product claims rely primarily on company website content and founder-linked posts, with limited independent corroboration from a June 2024 LinkedIn event post.

Where the Demand Sits

Public sources The market matters now because ADHD care is still measured largely through intermittent observation, while wearable data and remote monitoring have made continuous measurement more technically feasible, at least in narrow clinical workflows [Iluria Health] [LinkedIn, June 2024].

The available public record does not support a clean TAM, SAM, and SOM build for Iluria’s exact category, and that gap is material. What can be said from cited sources is narrower: Iluria positions itself at the intersection of ADHD treatment monitoring, remote patient monitoring, and digital mental health, with clinicians, mental-health providers, private clinics, healthcare providers, and payers named as target stakeholders in public materials [Iluria Health] [LinkedIn, March 2025]. Its reported clinical work with Clalit Health Services matters less as a revenue proxy than as a signal of where the company believes adoption could start, inside large care systems or adjacent specialty networks; Clalit is described in public sources as serving roughly five million people in Israel [Iluria Health] [Drooid].

That framing points to an addressable opportunity shaped more by workflow pain than by consumer app demand. Iluria’s own product claims focus on reducing the trial-and-error process in ADHD treatment by using physiological data from commercial wearables to provide ongoing feedback to clinicians and families [Iluria Health]. If that proposition holds in practice, the initial spend would likely come from specialty psychiatry, pediatric behavioral health, and private mental-health clinics rather than broad direct-to-consumer channels, which is consistent with the company’s public outreach for advisors connected to providers, payers, and potential customers [LinkedIn, March 2025].

The adjacent markets are clearer than the core market size. Iluria sits beside remote patient monitoring, digital therapeutics, wearable analytics, and clinical decision-support software, but it is not presented in public materials as a new drug, a novel wearable hardware company, or a general wellness app [Iluria Health] [LinkedIn, June 2024]. That distinction matters because substitute solutions likely include standard ADHD medication follow-up visits, parent and teacher rating scales, telepsychiatry workflows, and broader mental-health software rather than only other wearable-first ADHD platforms.

Regulation and reimbursement are harder to read from the public evidence, and caution is warranted. The cited materials establish clinical-trial activity and accelerator participation, including Health Wildcatters and the NHS Market Access Accelerator, but they do not establish commercial NHS deployment, payer coverage, or a cleared-device pathway [D Magazine, September 2020] [LinkedIn, June 2024]. For this market, the gating issues are less about headline interest in AI and more about whether a provider can trust the signal, fit it into clinical workflow, and justify payment under existing care models.

Market signal Public evidence Why it matters
Large potential clinical network Clalit Health Services is described as serving roughly 5 million people in Israel [Drooid] [Iluria Health] Suggests access to large-scale validation environments if partnerships deepen
Buyer orientation Public materials point to physicians, mental-health providers, private clinics, healthcare providers, and payers [LinkedIn, March 2025] [Iluria Health] Indicates a provider-led adoption path rather than a pure consumer app motion
Category adjacency Product is framed around wearable-based monitoring and clinical feedback, not hardware sales or therapeutics alone [Iluria Health] [LinkedIn, June 2024] Places Iluria in a mixed budget environment spanning digital health, monitoring, and decision support

The table shows a market story built from care-delivery context rather than from a published category size for "ADHD wearable monitoring." That is workable for an early company, but it leaves investors needing proof that clinical interest can convert into a reimbursable and repeatable buying motion.

Company-stated, unverified -- This section relies mainly on company materials and LinkedIn evidence, with limited third-party corroboration for the underlying market signals.

Competitive Landscape

MIXED Iluria is positioning itself against a broader set of alternatives than the startup record alone suggests, because ADHD treatment monitoring already sits between incumbent clinical judgment, adjacent digital-health workflows, and the consumer wearable stack that supplies its data inputs [Iluria Health] [LinkedIn, March 2025].

The immediate competitive map starts with incumbents rather than direct startup peers. In routine ADHD care, medication selection and dose adjustment are still often managed through clinician observation, parent or teacher reports, and follow-up visits, which means Iluria is asking providers to replace part of an established workflow with continuous physiological monitoring from commercial wearables [Iluria Health]. That puts its first competition in plain terms: status quo care pathways, not only other software vendors.

A second layer is adjacent digital health. Iluria's own materials point to physicians, mental-health providers, private mental-health clinics, healthcare providers, and payers as target stakeholders, and a 2025 advisory-board posting emphasized introductions to providers, payers, and potential customers [LinkedIn, March 2025] [Iluria Health]. That suggests overlap with remote patient monitoring vendors, behavioral-health software platforms, and clinic workflow tools that may not be ADHD-specific but already control budget, deployment, or clinician attention.

The more interesting question is where Iluria has an edge today, and the evidence supports a narrow answer. Its wedge is specificity: the company is not presenting a general telehealth product, but a precision-monitoring platform for ADHD treatment that analyzes movement, heart rate, and heart rate variability from commercial wearables and feeds that into machine-learning models for treatment decisions [Iluria Health]. If the reported clinical work with Cincinnati Children's Hospital Medical Center and Clalit Health Services translates into proprietary longitudinal datasets, that could become a durable data advantage, but the current public record only establishes clinical-trial participation, not commercial scale or a regulatory moat [Iluria Health] [Drooid].

That edge also looks perishable in two ways. First, the hardware layer is not proprietary, because Iluria relies on commercial wearables rather than a closed sensor stack, which lowers adoption friction but also limits product defensibility if a larger digital-health vendor builds a similar analytics layer on top of the same devices [Iluria Health]. Second, CB Insights lists "No Customer Deployments," and the surfaced hiring activity is concentrated in advisory-board roles rather than a visible go-to-market buildout, which leaves open the risk that better-capitalized adjacent platforms reach clinics first and define the operating standard before Iluria does [CB Insights] [LinkedIn, March 2025] [LinkedIn, December 2025].

The company's most exposed flank is distribution. Health Wildcatters and the NHS Market Access Accelerator add some ecosystem access, and Health Wildcatters was also named in Iluria's June 2022 financing update, but neither item establishes a recurring sales channel or a signed customer base [D Magazine, September 2020] [LinkedIn, June 2022] [LinkedIn, June 2024]. In practical terms, the company may be strongest when selling into private mental-health clinics that want a differentiated ADHD monitoring layer, and weakest if procurement shifts toward large health systems or payers that prefer broader platforms with established deployment histories.

The most plausible 18-month scenario is less a head-to-head startup race than a test of whether a focused ADHD workflow can secure early clinical adoption before adjacent categories absorb the use case. Clalit Health Services is the clearest winner if Iluria can convert trial work into a live care pathway inside a system serving roughly five million people, because validation from a scaled provider would matter more than a small financing delta [Drooid] [Iluria Health]. The loser if commercial traction does not appear is the independent ADHD-monitoring category itself, with Iluria most at risk, because public evidence today still leans on company claims, founder interviews, and accelerator affiliation rather than demonstrated customer deployment [CB Insights] [LinkedIn Pulse, January 2023] [D Magazine, September 2020].

Opportunity

Upside case

PUBLIC The prize here is not another wellness app, but a credible chance to become the monitoring layer that makes ADHD treatment more measurable for clinicians, families, and eventually payers, if wearable-derived signals can consistently show treatment response in real-world care [iluriahealth.com] [LinkedIn, June 2024].

The headline opportunity is fairly specific. Iluria is trying to insert itself into a part of ADHD care that still appears observational and iterative: medication selection and adjustment outside the clinic. Its public materials describe a precision-monitoring platform that uses physiological data from commercial wearables, including movement, heart rate, and heart rate variability, to give clinicians and families continuous feedback on treatment response [iluriahealth.com]. That is a narrower claim than diagnosis, and that matters. A decision-support layer for treatment monitoring is a more reachable wedge than trying to replace physicians or build a new hardware stack, particularly because the company says it works with commercial wearables and has completed clinical work with Cincinnati Children’s Hospital Medical Center and Clalit Health Services [iluriahealth.com]. The evidence is still company-led, but it points to a product aimed at workflow insertion rather than a science project.

A large outcome becomes reachable if that wedge proves useful in one buyer channel and then broadens. Iluria has publicly signaled interest in private mental-health clinics and other healthcare stakeholders, and one of its advisory-board postings explicitly emphasizes introductions to healthcare providers, payers, and potential customers [LinkedIn, March 2025]. The company also participated in Health Wildcatters and said it was accepted into the NHS Market Access Accelerator, both of which are consistent with a commercialization strategy that depends on healthcare distribution rather than direct-to-consumer acquisition [D Magazine, September 2020] [LinkedIn, June 2024]. That does not establish traction, but it does make the upside path legible.

Scenario What happens Catalyst Why it's plausible
Clinical-monitoring wedge Iluria becomes a specialist software layer used by ADHD-focused clinics to track medication response between visits A first repeatable deployment motion through private mental-health clinics or affiliated physician groups [LinkedIn, March 2025] The company has framed private clinics and providers as target stakeholders, and its product is already positioned around continuous treatment monitoring rather than diagnosis [LinkedIn, March 2025] [iluriahealth.com]
Health-system validation Iluria converts clinical-trial relationships into broader institutional credibility and care-pathway adoption Positive follow-on evidence or formal expansion with trial partners such as Clalit or Cincinnati Children’s Hospital Medical Center [iluriahealth.com] Iluria says it has completed clinical trials with those institutions, which gives it at least an initial evidentiary and relationship base if results support broader use [iluriahealth.com]
Payer-aligned infrastructure Iluria becomes a measurable-outcomes tool for payers or large providers seeking more objective ADHD-treatment management A partner that treats monitoring as a utilization or outcomes tool, not just a clinician convenience product [LinkedIn, March 2025] [LinkedIn, June 2024] The product claim is built around objective, continuous feedback, and the company’s own outreach names payers and healthcare providers as targets, which is directionally aligned with reimbursement or care-management use cases [LinkedIn, March 2025] [iluriahealth.com]

The compounding mechanism, if it appears, would come from data density and workflow fit rather than a classic consumer network effect. Every monitored patient could add more longitudinal physiological and treatment-response data, which in turn could sharpen personalization if the machine-learning claims hold up in practice [iluriahealth.com]. Because the system is built on commercial wearables rather than proprietary hardware, distribution could improve as clinicians grow comfortable prescribing a monitoring workflow that fits devices families may already know how to use [iluriahealth.com]. The early signs are limited, but the reported clinical studies, accelerator participation, and repeated advisory recruiting around provider and physician access suggest the company is at least trying to build this loop from evidence to channel to product refinement [Hagay Levy / LinkedIn] [D Magazine, September 2020] [LinkedIn, March 2025] [LinkedIn, December 2025].

The size of the win is harder to quantify because the public record here does not provide a strong third-party market model or a clean public comparable focused narrowly on ADHD-treatment monitoring. Still, there is one concrete anchor in the materials: Iluria has described Clalit Health Services as a clinical-trial partner, and Clalit is described in the available sources as serving roughly five million people [iluriahealth.com] [Drooid]. If Iluria eventually became embedded as a recognized monitoring layer across even a small portion of large-provider ADHD care pathways, the company could plausibly support a strategic software valuation measured in the hundreds of millions of dollars (scenario, not a forecast), especially if it can show that objective monitoring improves medication management, adherence, or clinician productivity. That remains an upside case, not an observed outcome, and the current public evidence is still much stronger on intent than on commercial proof.

Company-stated, unverified -- This section relies materially on company website claims and company-linked posts, with limited independent corroboration from D Magazine, LinkedIn job postings, and a secondary reference on Clalit scale.

Sources

Public sources

  1. [CB Insights, May 2022] Iluria | CB Insights | https://www.cbinsights.com/company/iluria

  2. [ContactOut] Iluria Health Ltd. Overview & Revenue | ContactOut | https://contactout.com/company/Iluria-Health-Ltd-12566

  3. [D Magazine, September 2020] Meet Health Wildcatters' Latest Cohort | D Magazine | https://www.dmagazine.com/healthcare-business/2020/09/meet-health-wildcatters-latest-cohort/

  4. [Drooid] Drooid | https://drooid.com/

  5. [Hagay Levy / LinkedIn] Hagay Levy | LinkedIn | https://www.linkedin.com/in/hagay-levy/

  6. [Iluria Health] iluria | https://www.iluriahealth.com/

  7. [Iluria LinkedIn, June 2022] Iluria LinkedIn Post | https://www.linkedin.com/posts/iluria_httpslnkdindntps-g-so-proud-to-have-activity-6939852889506877440-TD6a

  8. [LinkedIn, December 2025] Physician Board Member at Iluria | https://www.linkedin.com/jobs/view/physician-board-member-at-iluria-4348975760

  9. [LinkedIn, June 2024] Iluria Health: A New Venture for ADHD Treatment | https://www.linkedin.com/posts/benjamin-davis-smith_iluria-video-june-2023-eng-activity-7209609580681519105-qApq

  10. [LinkedIn, March 2025] Member of the Board of Advisors at Iluria | https://www.linkedin.com/jobs/view/member-of-the-board-of-advisors-at-iluria-4161952540

  11. [LinkedIn Pulse, January 2023] Interview with Hagay Levy, CEO and Co-founder of Iluria | https://www.linkedin.com/pulse/people-behind-healthcare-innovation-interview-hagay-levy-gila-tolub

  12. [PitchBook] Iluria Health | PitchBook | https://pitchbook.com/

  13. [Xceptional Leaders podcast, August 2026] Launching Iluria: Looking in on the Early Stages of a Startup with Hagay Levy | https://podcasts.apple.com/us/podcast/launching-iluria-looking-in-on-the-early-stages/id1435433350?i=1000779695151

Articles about Iluria Health

View on Startuply.vc